Mirabegron — Membership Pricing
Mirabegron is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Mirabegron Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $89.99 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Mirabegron
Mirabegron is a prescription medication. Ask your doctor if Mirabegron is right for you.
Conditions Treated with Mirabegron
How to Check Mirabegron Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Mirabegron at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Overactive Bladder
Other medications in Urology
About Mirabegron
Struggling with the urgency and frequency of an overactive bladder? Mirabegron offers a modern approach to managing these disruptive symptoms. At TheDrugClub, we believe effective treatment shouldn't break the bank. Mirabegron is a prescription medication primarily used to treat the symptoms of overactive bladder (OAB) in adults. OAB is a common condition characterized by a sudden, compelling urge to urinate that is difficult to defer (urinary urgency), often accompanied by increased frequency of urination (frequent urination) and waking up at night to urinate (nocturia). In some cases, it can also lead to urge incontinence, which is the involuntary leakage of urine associated with urgency. By effectively addressing these symptoms, Mirabegron helps improve bladder control and enhance the overall quality of life for individuals living with OAB. Unlike older OAB medications that often block nerve signals, Mirabegron works through a different mechanism. It belongs to a class of drugs called beta-3 adrenergic agonists. Specifically, Mirabegron targets and activates beta-3 receptors found in the bladder muscle. When these receptors are stimulated, the bladder muscle relaxes, allowing it to hold more urine and reducing the involuntary contractions that cause urgency and frequency. This relaxation helps to increase the bladder's storage
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Mirabegron is approved for (FDA label)
Mirabegron extended-release tablets are a beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) 1.1 Adult Overactive Bladder (OAB) Mirabegron Monotherapy Mirabegron extended-release tablets are indicated for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity (NDO) Mirabegron extended-release tablets are indicated for the treatment of NDO in pediatric patients aged 3 years and older and weighing 35 kg or more.
Source: Read the full FDA label on DailyMed. Label effective date: September 3, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Mirabegron (FDA label)
Extended-release tablets: 25 mg and 50 mg ( 3 ) Mirabegron extended-release tablets are supplied in two different strengths as described below: 50 mg yellow colored, oval shaped, biconvex, film-coated tablets debossed with "1160" on one side and plain on other side.
Source: FDA prescribing information (DailyMed). Set ID: 5f7a1758-8691-4e53-96d6-a01626ee8140. SPL document ID: 5a9956d6-df8d-d72e-e063-6394a90a2126. Label effective date: September 3, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Mirabegron (FDA label)
The following adverse reactions are discussed in more detail in other sections of the labeling.
Source: FDA prescribing information (DailyMed). Set ID: 5f7a1758-8691-4e53-96d6-a01626ee8140. SPL document ID: 5a9956d6-df8d-d72e-e063-6394a90a2126. Label effective date: September 3, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Mirabegron (FDA label)
Mirabegron extended-release tablets are contraindicated in patients with known hypersensitivity reactions to mirabegron or any inactive ingredients of the tablet [see Adverse Reactions ( 6.1 , 6.2 )]. Hypersensitivity to mirabegron or any inactive ingredients. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 5f7a1758-8691-4e53-96d6-a01626ee8140. SPL document ID: 5a9956d6-df8d-d72e-e063-6394a90a2126. Label effective date: September 3, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Mirabegron (FDA label)
Increases in Blood Pressure: Can increase blood pressure in adult or pediatric patients. Periodically monitor blood pressure, especially in hypertensive patients. Mirabegron extended-release tablets are not recommended in patients with severe uncontrolled hypertension. ( 5.1 ) Urinary Retention in Patients with Bladder Outlet Obstruction and in Patients Taking Muscarinic Antagonist Drugs for Overactive Bladder: Administer with caution in these patients because of risk of urinary retention. ( 5.2 ) Angioedema: Angioedema of the face, lips, tongue and/or larynx has been reported with mirabegron. ( 5.3 , 6.2 ) 5.1 Increases in Blood Pressure Increases in Blood Pressure in Adults Mirabegron can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients.
Source: FDA prescribing information (DailyMed). Set ID: 5f7a1758-8691-4e53-96d6-a01626ee8140. SPL document ID: 5a9956d6-df8d-d72e-e063-6394a90a2126. Label effective date: September 3, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Mirabegron (FDA label)
Drug interaction studies were conducted in adult patients to investigate the effect of coadministered drugs on the pharmacokinetics of mirabegron and the effect of mirabegron on the pharmacokinetics of coadministered drugs (e.g., ketoconazole, rifampin, solifenacin succinate, tamsulosin, and oral contraceptives) [see Clinical Pharmacology ( 12.3 )] . No dose adjustment is recommended when these drugs are coadministered with mirabegron.
Source: FDA prescribing information (DailyMed). Set ID: 5f7a1758-8691-4e53-96d6-a01626ee8140. SPL document ID: 5a9956d6-df8d-d72e-e063-6394a90a2126. Label effective date: September 3, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.